Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC.

[1]  X. Yi,et al.  Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer , 2020, Cell Death & Disease.

[2]  D. Ledbetter,et al.  Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention , 2020, Science.

[3]  Edward S. Kim,et al.  Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer , 2020, JAMA oncology.

[4]  D. Berry,et al.  Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  E. Helman,et al.  Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer , 2020, Clinical Cancer Research.

[6]  Ash A. Alizadeh,et al.  A mathematical model of ctDNA shedding predicts tumor detection size , 2020, Science Advances.

[7]  Harry J de Koning,et al.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. , 2020, The New England journal of medicine.

[8]  A. Hackshaw,et al.  P1.11-19 Trial in Progress: Cancer Screening Study With or Without Low Dose Lung CT to Validate a Multi-Cancer Early Detection Blood Test , 2019, Journal of Thoracic Oncology.

[9]  J. Ptak,et al.  Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. , 2019, JAMA oncology.

[10]  Ying Cheng,et al.  Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. , 2019, Journal of Clinical Oncology.

[11]  S. Shchegrova,et al.  Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer , 2019, JAMA oncology.

[12]  R. Scharpf,et al.  Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. , 2019, Cancer research.

[13]  Sharyn I. Katz,et al.  Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer , 2019, JAMA oncology.

[14]  R. Scharpf,et al.  Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2018, Cancer research.

[15]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  J. Roth,et al.  MA23.02 Circulating Tumor DNA Analysis with a Novel Variant Classifier for Recurrence Detection in Resected, Early-Stage Lung Cancer , 2018, Journal of Thoracic Oncology.

[17]  A. Gupta,et al.  Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab , 2018, Clinical Cancer Research.

[18]  Jacob Silterra,et al.  Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab , 2018, Nature Medicine.

[19]  Joon-Oh Park,et al.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer , 2018, Nature Medicine.

[20]  C. Paweletz,et al.  Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies , 2018, Clinical Cancer Research.

[21]  Ash A. Alizadeh,et al.  Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. , 2017, Cancer Discovery.

[22]  Maximilian Diehn,et al.  Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers , 2017, Nature Genetics.

[23]  S. Morbelli,et al.  Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer: 18F-FDG PET/CT Study , 2017, The Journal of Nuclear Medicine.

[24]  Ashwini Naik,et al.  Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.

[25]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[26]  H. Ye,et al.  Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing , 2016, Scientific Reports.

[27]  Suzanne E Dahlberg,et al.  Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. , 2016, JAMA oncology.

[28]  S. Mortimer,et al.  Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. , 2016 .

[29]  Chandra Sekhar Pedamallu,et al.  Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas , 2016, Nature Genetics.

[30]  B. Kermani,et al.  Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA , 2015, PloS one.

[31]  Jorge S. Reis-Filho,et al.  Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer , 2015, Science Translational Medicine.

[32]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[33]  Kyoungjune Pak,et al.  Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Vadgama,et al.  The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients , 2013, International journal of molecular sciences.

[36]  T. Mitsudomi,et al.  Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  John L. Humm,et al.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[38]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[39]  W. El-Deiry,et al.  Clinical implications of p53 mutations in lung cancer. , 2003, Methods in molecular medicine.